Sutro Biopharma (STRO) Profit After Tax (2017 - 2026)

Sutro Biopharma has reported Profit After Tax for 9 years, with the latest figure at -$46.8 million in Q4 2025.

• Quarterly Profit After Tax rose 35.45% year-over-year to -$46.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$191.1 million (up 15.99% YoY) and the FY2025 annual result came in at -$191.1 million, up 15.99% from the prior year.
• Profit After Tax climbed to -$46.8 million in Q4 2025 per STRO's latest filing, from -$56.9 million in the prior quarter.
• Over five years, Profit After Tax peaked at $31.1 million in Q4 2023 and troughed at -$76.0 million in Q1 2025.
• A 5-year average of -$37.5 million and a median of -$38.8 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax soared 189.8% in 2023, then plunged 333.2% in 2024.
• Over 5 years, Profit After Tax stood at -$38.1 million in 2021, then climbed by 9.26% to -$34.6 million in 2022, then jumped by 189.8% to $31.1 million in 2023, then slumped by 333.2% to -$72.4 million in 2024, then surged by 35.45% to -$46.8 million in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered -$46.8 million, -$56.9 million, and -$11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.